A Florida safety-net hospital is fighting back against Eli Lilly's controversial 340B data demands. Tampa General Hospital has filed a lawsuit accusing Lilly of "unconscionable" practices after the drugmaker cut off its federally mandated discounts for refusing to submit claims-level data. The hospital says it's now paying 25–50% more for Lilly drugs, with vulnerable patients bearing the ultimate cost.
Tampa General Hospital, a nearly 1,000-bed safety-net facility in Florida, has filed a federal lawsuit against Eli Lilly after the pharmaceutical giant revoked its 340B program discounts — a federal subsidy designed to help hospitals serving low-income patients afford medications. Lilly's policy requires providers to submit claims-level data for all drug dispensations, threatening to pull discounts for those that don't comply. Tampa General refused, and Lilly followed through, leaving the hospital paying significantly more for drugs it often has no alternative source for.
The lawsuit, filed in the U.S. District Court for the Middle District of Florida, accuses Lilly of violating the Florida Deceptive and Unfair Trade Practices Act, citing the company's alleged monopoly power over certain drug markets. Tampa General argues the data demands impose heavy administrative burdens and effectively raise costs even for hospitals that comply. Lilly, for its part, says the data is needed to root out fraud and abuse in the 340B program and that hospitals already share this information with insurers.
By the Numbers:
Why it matters: This lawsuit is one of the first direct legal challenges to Lilly's 340B data policy and could set a precedent for how drugmakers and safety-net hospitals navigate the increasingly contentious 340B landscape — with real consequences for patient access to affordable care.
